Study of the pharmacokinetics of extended release sildenafil

Capa

Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Somente assinantes

Resumo

Purpose of the study. Comparison of the pharmacokinetic characteristics of the drug Vildegra® registered in the Russian Federation with literature data for the original drug Viagra®.

Materials and methods. Study design: prospective, open-label in healthy volunteers with a single oral dose on an empty stomach. The study included 48 male volunteers aged 18 to 45 years with a verified diagnosis of “healthy.” All subjects of the clinical study took 1 tablet of Vildegra® once on an empty stomach. Blood samples to determine the concentrations of active substances were taken before taking the study drug and then after 0.25; 0.5; 0.75; 1; 1.5; 2; 2.5; 3; 3.5; 4; 4.5; 5; 5.5; 6; 7; 8; 10; 12; 16; 24; 30; 36; 48 and 72 hours after taking the drug. Dynamic monitoring was carried out throughout the study, including clinical examination, measurement of vital signs, monitoring of laboratory parameters and monitoring of adverse events (AE). The concentrations of sildenafil and its active metabolite N-desmethylsildenafil in the blood plasma of volunteers were determined by high-performance liquid chromatography with tandem mass spectrometric detection. Pharmacokinetic parameters were calculated using a model-free method using the specialized program PK Solution2.0.

Results. The AUC0-t, AUC0-∞ and Cmax values for sildenafil and its active metabolite when taking the drug Vildegra are in good agreement with the literature data for the original drug Viagra. The values of tmax and t1/2 of the drug Vildegra® are slightly higher than those of the original drug, which is apparently explained by the extended-release dosage form in the case of Vildegra®. In 10 of 48 volunteers (21%), 20 AE were recorded, which resulted in complete recovery. No serious or unexpected AE were noted.

Conclusion. The results obtained allow us to conclude that the pharmacokinetics, good tolerability and satisfactory safety profile of the drug Vildegra® are comparable with the published data for the original drug Viagra®.

Sobre autores

I. Kurta

RZD Medicine Central Clinical Hospital

Autor responsável pela correspondência
Email: Dr.Kurta@yandex.ru

Researcher at the Laboratory of Pharmacokinetics

Rússia, Moscow

A. Zakharova

RZD Medicine Central Clinical Hospital

Email: labfkr@mail.ru

PhD of Medical Sciences, Clinical Pharmacologist

Rússia, Moscow

D. Guranda

Pharm InnTech LLC; Lomonosov Moscow State University

Email: dorel@belozersky.msu.ru

PhD in Chemistry, CEO; Senior Researcher, Laboratory of Enzymatic Modifications of Physiologically Active Compounds, A. N. Belozersky Research Institute of Physical-Chemical Biology

Rússia, Moscow; Moscow

A. Kuzmin

RZD Medicine Central Clinical Hospital

Email: labfkr@mail.ru

Leading Clinical Research Specialist

Rússia, Moscow

F. Isakov

RZD Medicine Central Clinical Hospital

Email: labfkr@mail.ru

Anesthesiologist Resuscitator

Rússia, Moscow

R. Shaburov

RZD Medicine Central Clinical Hospital

Email: labfkr@mail.ru

PhD of Medical Sciences, Chief Physician

Rússia, Moscow

V. Belolipetskaya

RZD Medicine Central Clinical Hospital

Email: labfkr@mail.ru

PhD in Biology, Leading Clinical Research Specialist

Rússia, Moscow

Bibliografia

  1. Wespes E., Amar E., Hatzichristou D. et al. EAU Guidelines on Erectile Dysfunction: An Update. Eur Urol. 2006;49:806–815. doi: 10.1016/j.eururo.2006.01.028.
  2. Laumann E.O., Paik A., Rosen R.C. Sexual dysfunction in the United States. J Am Med Assoc. 1999;281:537–544. doi: 10.1001/jama.281.6.537.
  3. McKinlay I. The worldwide prevalence and epidemiology of erectile dysfunction. Int. J. Impot: res. 2000;(suppl.4):56–511.
  4. Feldman H.A., Goldstein I., Hatrichriston D.G. et al. Impotence and its medical and psychological correlatesresults of the Massachusetts Male Aging Study. I.Urol. (Baltimore)1999;151:54–61.
  5. Pushkar D.Yu., Kamalov A.A., Al-Shukri S.H., etc. Epidemiological study of the prevalence of erectile dysfunction in the Russian Federation. RMZH. 2012;3:112. Russain (Пушкарь Д.Ю., Камалов А.А., Аль-Шукри С.Х. и др. Эпидемиологическое исследование распространенности эректильной дисфункции в Российской Федерации. РМЖ. 2012;3:112).
  6. Gamidov S.I., Ovchinnikov R.I., Popova A.Yu., Shatylko T.V. Risk factors for erectile dysfunction: known and unexpected facts (review). Andrologiya i genital’naya khirurgiya = Andrology and Genital Surgery 2021;22(4):13–21. doi: 10.17650/1726-9784-2021-22-4-13-21. Russian (Гамидов С.И., Овчинников Р.И., Попова А.Ю., Шатылко Т.В. Факторы риска развития эректильной дисфункции: известные и неожиданные факты. Андрология и генитальная хирургия. 2021;22(4):13–21. doi: 10.17650/1726 9784 2021 22 4 13 21).
  7. Kubin M., Wagner G., Fugl-Meyer A.R. Epidemiology of erectile dysfunction. Int J Impot Res. 2003;15(1):63–71. doi: 10.1038/sj.ijir.3900949.
  8. Liu C., Lopez D.S., Chen M., Wang R. Penile Rehabilitation Therapy Following Radical Prostatectomy: A Meta-Analysis. J Sex Med. 2017;14(12):1496–1503.
  9. Gafarov R.R., Shodmonova Z.R., Allazov S.A., Khamroev G.A., Tukhtaev F.M. Phosphodiesterase inhibitors of type 5 are the first line of therapy for erectile dysfunction. Achievements of science and education. 2020;5(59):103–108. Russian (Гафаров Р.Р., Шодмонова З.Р., Аллазов С.А., Хамроев Г.А., Тухтаев Ф.М. Ингибиторы фосфодиэстеразы 5 типа – первая линия терапии эректильной дисфункции. Достижения науки и образования. 2020;5 (59):103–108).
  10. Pushkar D.Yu., Nosovitsky P.B. Phosphodiesterase inhibitors of the fifth type: new data. Pharmateca. 2005;11:21–25. Russian (Пушкарь Д.Ю., Носовицкий П.Б. Ингибиторы фосфодиэстеразы пятого типа: новые данные. Фарматека. 2005;11:21–25).
  11. Helsinki Declaration of the World Medical Association (revised version approved by the 64th session of the General Assembly, Fortaleza, Brazil, October 2013). Russian (Хельсинкская декларация Всемирной медицинской ассоциации (редакция, одобренная 64-й сессией Генеральной ассамблеи, Форталеза, Бразилия, октябрь 2013 г.).
  12. Federal Law of the Russian Federation No. 61-FZ dated April 12, 2010 “On the Circulation of Medicines». Russian (Федеральный закон Российской Федерации от 12 апреля 2010 года N 61-ФЗ “Об обращении лекарственных средств”).
  13. The National standard of the Russian Federation «Good clinical practice» (GOST R52379-2005) dated 09/25/2005. Russian (Национальный стандарт Российской Федерации «Надлежащая клиническая практика» [ГОСТ Р52379-2005] от 25.09.2005).
  14. The State Register of Medicines of the Ministry of Health of the Russian Federation, instructions for the medical use of the drug «Viagra» (registration no. N015875/01)[request date: June 05, 2024]. Available by: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=c758d8f4-97d0-4d07-906e-539c5f07158b&t=. Russian (Государственный реестр лекарственных средств Минздрава РФ, инструкция по медицинскому применению лекарственного препарата «Виагра» (регистрационный № П N015875/01)[дата запроса: 05 Июня 2024]. Доступно по: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=c758d8f4-97d0-4d07-906e-539c5f07158b&t=).
  15. Nichols D.J., Muirhead G.J., Harness J.A. Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. Br J Clin Pharmacol. 2002;53 Suppl 1(Suppl 1):5S-12S. doi: 10.1046/j.0306-5251.2001.00027.x.
  16. Radicioni M., Castiglioni C., Giori A., Cupone I., Frangione V., Rovati S. Bioequivalence study of a new sildenafil 100 mg orodispersible film compared to the conventional film-coated 100 mg tablet administered to healthy male volunteers. Drug Des DevelTher. 2017;11:1183–1192. doi: 10.2147/DDDT.S124034.
  17. Shaw A., Lawrence T.E., Yan T., Liu M., Summers N., Daggumati V., Austria S.T., Rondon J.C., Hackley S., Vignesh S.O., Hassan T.A. Bioequivalence Studies of Sildenafil Citrate Orodispersible Film Administered with and without Water vs ViagraⓇ Film-Coated Tablets in Healthy Male Volunteers. Curr Ther Res Clin Exp. 2023;99:100708. doi: 10.1016/j.curtheres.2023.100708.
  18. Bioequivalence of 2 Formulations of Sildenafil Oral Soluble Film 100 mg and Sildenafil Citrate (Viagra) 100 mg Oral Tablets in Healthy Male Volunteers/ American Journal of Therapeutics: July/August 2017;24(4):e373–e380.
  19. Assessment report for Sildenafil ratiopharm. European Medicines Agency, Doc. Ref.: EMA/793633/2009.[дата запроса: 05 Июня 2024] URL:https://www.ema.europa.eu/en/documents/assessment-report/sildenafil-ratiopharmepar-public-assessment-report_en.pdf
  20. Sildenafil and N-desmethyl sildenafil quantification in human plasma by HPLC coupled with ESI-MS/MS detection: Application to bioequivalence study/ Balasekhara Reddy Challa et al. – Journal Analytical Methods. 2010;2:1043–1050.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar
2. Figure. Averaged pharmacokinetic profiles of sildenafil (blue) and N-desmethylsildenafil (red)

Baixar (351KB)
Metadados

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies